Vaccine Info

VTP-500 MERS Vaccine

Authored by
Staff
Last reviewed
October 13, 2021
Fact checked by
Robert Carlson, MD
Share

VTP-500 MERS Vaccine Description

VTP-500 (ChAdOx1) MERS is a vaccine candidate to treat MERS Coronaviruses (CoV). The ChAdOx1 MERS vaccine contains the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.

Vaccitech’s VTP-500 MERS vaccine utilizes the ChAdOx1 virus platform to encode MERS coronavirus spike protein to induce T cells and antibodies that block virus-host cell receptor binding and fusion or neutralize virus infection.

Vaccitech’s partner, the University of Oxford’s Jenner Institute, in collaboration with The King Abdullah International Medical Research Centre (KAIMRC), announced on December 20, 2019, that it has started a Phase I clinical trial in the Kingdom of Saudi Arabia (KSA) for a vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Vaccitech retains commercial rights to this vaccine.

The patented Vaccitech adenovirus vectors are known as chimpanzee adenovirus Oxford 1 and 2 (ChAdOx1 and ChAdOx2) and are in the group E simian adenovirus family, similar to the widely-studied chimpanzee adenovirus 63. These viruses have been engineered to be replication-deficient and manufactured in well-established HEK293 cell lines containing the adenoviral E1 gene.

Vaccitech has licensed the needed patents from Oxford University to advance its programs. ChAdOx1 vector patent was granted in the US and the EU, and our MVA-NP+M1 patent is granted in the EU and pending in the US. Vaccitech retains commercial rights for the product while licensing certain rights back to Oxford for the non-profit development of the vaccine.

Oxford, England-based Vaccitech (NASDAQ: VACC) is a T cell immunotherapy and vaccine company originally with the University of Oxford’s Jenner Institute. The Company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, and the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. 

VTP-500 MERS Coronavirus Vaccine Indication

VTP-500 (ChAdOx1) is a vaccine candidate protecting people against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the novel SARS-CoV-2 coronavirus.

VTP-500 MERS Coronavirus Vaccine News

August 12, 2021 - Vaccitech plc announced its financial results for the second quarter, ended June 30, 2021, and provided an overview of the Company’s recent corporate developments. 

April 29, 2021 - Vaccitech plc announced the pricing of its initial public offering in the United States for total gross proceeds of $110.5 million.

March 22, 2021 - Vaccitech Ltd. announces Joseph Scheeren, PharmD, as an independent director to its Board of Directors.

August 21, 2020 - CEPI, Oxford University, and Janssen have entered into a collaboration worth up to $19M to progress the vaccine through Phase 2 studies and establish a human vaccine stockpile with the University. 

June 10, 2020 - RESEARCH ARTICLE: A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques.

April 17, 2020 - NIH press release: Investigational chimp adenovirus MERS-CoV vaccine protects monkeys. Vaccine neutralizes multiple MERS-CoV strains.

December 20, 2019 - Vaccitech’s partner, the University of Oxford’s Jenner Institute, in collaboration with The King Abdullah International Medical Research Centre (KAIMRC), announced that it had started a Phase I clinical trial in the Kingdom of Saudi Arabia (KSA) for a vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Vaccitech retains commercial rights to this vaccine. The trial will be the first Phase I clinical trial ever conducted in the KSA and provide valuable clinical data. The trial collaborates between the Jenner Institute and the King Abdullah International Medical Research Center (KAIMRC), funded by the Department of Health and Social Care.

November 8, 2019 - Study: Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels. Overall, the vaccination reduced virus shedding and nasal discharge (p = 0.0059 and p = 0.0274, respectively). The vaccine enhanced antibody responses in seropositive camels; these camels had a higher average age than seronegative. Older seronegative camels responded more strongly to vaccination than younger animals, and neutralizing antibodies were detected in nasal swabs.

VTP-500 MERS Coronavirus Vaccine Clinical Trials

Clinical Trial NCT04170829A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine. This research was funded by the Department of Health and Social Care (project number:16/107/01) as part of the UK Vaccine Network (UKVN), a UK Aid program to develop vaccines for diseases with epidemic potential in low and middle-income countries.

Clinical Trial NCT03399578: Suspended (The SARS-CoV-2 pandemic delayed recruitment but also provided an opportunity to apply findings from the rapid development of a ChAdOx1-vectored vaccine against SARS-CoV-2 to the further development of the MERS vaccine)

This was a clinical trial in which healthy volunteers were administered an experimental MERS vaccine. The vaccine ChAdOx1 MERS will be administered alone both as a single administration and with a homologous prime-booster.

Clinical Trials

No clinical trials found